Ras Oncogene Mutations in Urine Sediments of Patients with Bladder Cancer

  • Buyru, Nur (Molecular Oncology and Hematopathology Research Center, Cerrahpasa Medical Faculty, Istanbul University) ;
  • Tigli, Hatice (Molecular Oncology and Hematopathology Research Center, Cerrahpasa Medical Faculty, Istanbul University) ;
  • Ozcan, Faruk (Department of Urology, Istanbul Medical Faculty, Istanbul University) ;
  • Dalay, Nejat (Oncology Institute, Istanbul University)
  • Received : 2003.01.13
  • Accepted : 2003.03.01
  • Published : 2003.07.31


Early detection of bladder cancer is particularly important since it dramatically affects the survival rates. However, neither urinary cytology nor tumor markers that are currently used are sensitive enough for the early detection of bladder cancer or recurrent disease. The ras genes are frequently mutated in cancer. In this study, we investigated the diagnostic potential of ras mutation analysis in urinary sediments of patients with bladder cancer using a single-strand conformation polymorphism analysis and polymerase chain reaction. Mutation in codon 12 of the H-ras gene was observed in 39% of the patients. Our results indicate that this approach may significantly improve diagnostic sensitivity in detecting bladder tumors.


Ras mutations;Bladder cancer;Urimary sediments


Supported by : Istanbul University


  1. Barbacid, M. (1987) ras genes. Annu. Rev. Biochem. 56, 779-827.
  2. Boman, H., Hedelin, H. and Holmang, S. (2002) Four bladder tumor markers have a disappointingly low sensitivity for small size and low grade recurrence. J. Urol. 167, 80-83.
  3. Bos, J. L. (1989) Ras oncogenes in human cancer: a review. Cancer Res. 48, 4682-4689.
  4. Brown, K., Buchmann, A. and Balmain A. (1990) Carcinogeninduced mutations in the mouse c-Ha-ras gene provide evidence of multiple pathways for tumor progression. Proc. Natl. Acad. Sci. USA 87, 538-542.
  5. Burchill, S. A., Lunec, J., Mellon, K. and Neal, D. E. (1991) Analysis of H-ras mutations in primary human bladder tumors. Br. J. Cancer 63, 62.
  6. Burchill, S. A., Neal, D. E. and Lunec, J. (1994) Frequency of Hras mutations in human bladder cancer detected by direct sequencing. Br. J. Urol. 73, 516-521.
  7. Czerniak, B., Cohen, G. L., Etkind, P., Deitch, D., Simmons, H.,Herz, F. and Koss, L. G. (1992) Concurrent mutations of coding and regulatory sequences of the H-ras gene in urinary bladder carcinomas. Hum. Pathol. 23, 1199-1204.
  8. Czerniak, B., Deitch, D., Simmons, H., Etkind, P., Herz, F. and Koss, L. G. (1990) Ha-ras gene codon 12 mutation and DNA ploidy in urinary bladder carcinoma. Br. J. Cancer 62, 762-763.
  9. Fitzgerald, J. M., Ramchurren, N., Rieger, K., Levesque, P.,Silverman, M., Libertino, J. A. and Summerhayes, I. C. (1995) Identification of H-ras mutations in urine sediments complements cytology in the detection of bladder tumors. J. Natl. Cancer Inst. 87, 129-133.
  10. Fujita, J., Srivastava, S. K., Kraus, M. H., Rhim, J. S., Tronick, S. R. and Aaronson, S. A. (1985) Frequency of molecular alterations affecting ras protooncogenes in human urinary tract tumors. Proc. Natl. Acad. Sci. USA 82, 3849-3853.
  11. Hoffmann, J. S., Fry, M., Williams, J. and Loeb, L. A. (1993) Codon 12 and 13 of H-ras protooncogene interrupt the progression of DNA synthesis catalyzed by DNA polymerase alpha. Cancer Res. 53, 2895-2900.
  12. Hruban, R. H., van der Riet, P., Erozan, Y. S. and Sidransky, D.(1994) Brief report: Molecular biology and the early detection of carcinoma of the bladder-The case of Hubert H. Humphrey. N. Engl. J. Med. 330, 1276-1278.
  13. Knowles, M. A. and Williamson, M. (1993) Mutation of H-ras is infrequent in bladder cancer: Confirmation by single-strand conformation polymorphism analysis, designed restriction fragment length polymorphisms and direct sequencing. Cancer Res. 43, 133-139.
  14. Kopreski, M. S., Benko, F. A., Kwee, C., Leitzel, K. E., Eskander, E., Lipton, A. and Gocke, C. D. (1997) Detection of mutant Kras DNA in plasma or serum of patients with colorectal cancer. Br. J. Cancer 76, 1293-1299.
  15. Krengel, U., Schlichting, L., Scherer, A., Schumann, R., Frech,M., John, J., Kabsch, W., Pai, E. F. and Wittinghofer, A. (1990) Three-dimensional structures of H-ras p21 mutants: Molecular basis for their inability to function as signal switch molecules. Cell 62, 539-548.
  16. Krontiris, T. G., Devlin, B., Karp, D. D., Robert, N. J. and Rish,N. (1993) An association between the risk of cancer and mutations in the HRAS1 minisatellite locus. N. Engl. J. Med. 329, 517-523.
  17. Levesque, P., Ramchurren, N., Saini, K., Joyce, A., Libertino, J.and Summerhayes I. C. (1993) Screening of human bladder tumors and urine sediments for the presence of H-ras mutations. Int. J. Cancer 55, 785-790.
  18. Levi, S. Urbano-Ispizua, A., Gill, R., Thomas, D. M., Gilbertson,J., Foster, C. and Marshall, C. J. (1991) Multiple K-ras codon 12 mutations in cholangiocarcinomas demonstrated with a sensitive polymerase chain reaction technique. Cancer Res. 51, 3497-3502.
  19. Marshall, C. J. (1988) The ras oncogenes. J. Cell Sci. 10 (suppl), 157-169.
  20. Mills, N. E., Fishman, C. L., Scholes, J., Anderson, S. E., Rom,W. N. and Jacobson, D. R. (1995) Detection of ras oncogene mutations in bronchoalveolar lavage fluid for lung cancer diagnosis. J. Natl. Cancer Inst. 87, 1056-1060.
  21. Murphy, W. M., Soloway, M. S., Jukkola, A. F., Crabtree, W. N.and Ford, K. S. (1984) Urinary cytology and bladder cancer: the cellular features of transitional cell neoplasms. Cancer 53, 1555-1565.<1555::AID-CNCR2820530723>3.0.CO;2-G
  22. Olderoy, G., Daehlin, L. and Ogreid, D. (1998) Low frequency mutation of Ha-ras and Ki-ras oncogenes in transitional cell carcinoma of the bladder. Anticancer Res. 18, 2675-2678.
  23. Przybojewskai, B., Jagiello, A. and Salmuzna, P. (2000) H-ras, Kras and N-ras gene activation in human bladder cancers. Cancer Genet. Cytogenet. 121, 73-77.
  24. Puig, P., Urgell, E., Capella, G., Sancho, F. J., Pujol, J., Boadas,J., Farre, A., Lluis, F., Gonzalez-Sastre, F. and Mora, J. (2000) A highly sensitive method for K-ras mutation detection is useful in diagnosis of gastrointestinal cancer. Int. J. Cancer 85, 73-77.<73::AID-IJC13>3.0.CO;2-#
  25. van Rhijn, B. W. G., Lurkin, I., Kirkels, W. J., van der Kwast, T.H. and Zwarthoff, E. C. (2001) Microsatellite analysis- DNA test in urine competes with cystoscopy in follow-up of superficial bladder cancer. Cancer 92, 768-775.<768::AID-CNCR1381>3.0.CO;2-C
  26. Saito, S., Hata, M., Fukuyama, R., Sakai, K., Kudoh, J., Tazaki,H. and Shimizu, N. (1997) Screening of H-ras gene point mutations in 50 cases of bladder carcinoma. Int. J. Urol. 4, 178-185.
  27. Sarosdy, M. F., Hudson, M. A., Ellis, W. J., Soloway, M. S.,deVere W. R., Sheinfeld, J., Jarowenko, M. V., Schellhammer,P. F., Schervish, E. W., Patel, J. V., Chodak, G. W., Lamm, D.L., Johnson, R. D., Henderson, M., Adams, G., Blumenstein,B. A., Thoelke, K. R., Pfalzgraf, R. D., Murchison, H. A. andBrunelle, S. L. (1997) Improved detection of recurrent bladder cancer using the Bard BTAstat test. Urology 50, 349-353.
  28. Seripa, D., Parrella, P., Gallucci, M., Gravina, C., Papa, S.,Fortunato, P., Alcini, A., Flammia, G., Lazzari, M. and Fazio,V. M. (2001) Sensitive detection of transitional cell carcinoma of the bladder by microsatellite analysis of cells exfoliated in urine. Int. J. Cancer 95, 364-369.<364::AID-IJC1064>3.0.CO;2-V
  29. Serretta, V., Lo Presti, D., Vasile, P., Gange, E., Esposito, E. andMenozzi, I. (1998) Urinary NMP22 for the detection of recurrence after transurethral resection of transitional cell carcinoma of the bladder. Urology 52, 793-796.
  30. So, E. Y., Jang, J. Y. and Lee, C. E. (2001) Cross-talk between STAT6 and ras/MAPK pathway for the IL-4-mediated T cell survival. J. Biochem. Mol. Biol. 34, 578-583.
  31. Theoderescu, D., Cornil, I., Fernandez, B. J. and Kerbel, R. S.(1990) Overexpression of normal and mutated forms of H-ras induces orthotopic bladder invasion in a human transitional cell carcinoma. Proc. Natl. Acad. Sci. USA 87, 9047-9051.
  32. Tong, L., Milburn, M. V., deVos, A. M. and Kim, S. H. (1989) Structure of ras protein. Science 245, 244.
  33. Tong, L., de Vos A. M., Milburn, M. V., Jancarik, J., Noguchi, S.,Nishimura, S., Miura, K., Ohtsuka, E. And Kim, S. H. (1989) Structural differences between a ras oncogene protein and the normal protein. Nature 337, 90-93.
  34. Visvanathan, K. V., Pocock, R. D. and Summerhayes, I. C. (1988)Preferential and novel activation of H-ras in human bladder carcinomas. Oncogene Res. 3, 77-86.
  35. Wiener, H. G., Mian, C., Jaitel, A., Pycha, A., Schatzl, G. and Marberger, M. (1998) Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer? J. Urol. 159, 1876-1880.
  36. Young, M. J. and Soloway, M. S. (1998) Office evaluation and management of bladder neoplasms. Urol. Clin. North Am. 25, 603-611.

Cited by

  1. Altered Gene Expression Profile in Mouse Bladder Cancers Induced by Hydroxybutyl(butyl)nitrosamine vol.6, pp.5, 2004,
  2. Molecular targeting in the treatment of either advanced or metastatic bladder cancer or both according to the signalling pathways vol.18, pp.5, 2008,
  3. Biomarkers in bladder cancer: Translational and clinical implications vol.89, pp.1, 2014,
  4. Induction of G1 cell cycle arrest and apoptosis by berberine in bladder cancer cells vol.661, pp.1-3, 2011,
  5. The Interplay between ROS and Ras GTPases: Physiological and Pathological Implications vol.2012, 2012,
  6. Synergistic induction of cancer cell death and reduction of clonogenic resistance by cisplatin and FK228 vol.436, pp.2, 2013,
  7. Gene Expression Profiling of Chemically Induced Rat Bladder Tumors vol.9, pp.3, 2007,
  8. Involvement of the PLCε/PKCα pathway in human BIU-87 bladder cancer cell proliferation vol.35, pp.10, 2011,
  9. Methylation pattern of oncogene HRAS gene promoter region and its clinical relevance to urocystic tumorigenesis vol.39, pp.8, 2012,
  10. Matrix Metalloproteinases and Bladder Cancer: What is New? vol.2012, 2012,
  11. T-786C, G894T, and Intron 4 VNTR (4a/b) Polymorphisms of the Endothelial Nitric Oxide Synthase Gene in Bladder Cancer Cases vol.16, pp.6, 2015,
  12. Role of reactive oxygen species in proapoptotic ability of oncogenic H-Ras to increase human bladder cancer cell susceptibility to histone deacetylase inhibitor for caspase induction vol.135, pp.11, 2009,
  13. Knockdown of Phospholipase C-Epsilon by Short-Hairpin RNA-Mediated Gene Silencing Induces Apoptosis in Human Bladder Cancer Cell Lines vol.28, pp.3, 2013,
  14. Current Status of Targeted Therapy in Metastatic Transitional Cell Carcinoma of the Bladder vol.39, pp.5, 2012,
  15. Molecular prognostic factors in bladder cancer vol.95, pp.6, 2005,
  16. Urothelial tumorigenesis: a tale of divergent pathways vol.5, pp.9, 2005,
  17. Oncogenic H-Ras, FK228, and exogenous H2O2 cooperatively activated the erk pathway in selective induction of human urinary bladder cancer j82 cell death vol.50, pp.3, 2011,
  18. Differential induction of reactive oxygen species through Erk1/2 and Nox-1 by FK228 for selective apoptosis of oncogenic H-Ras-expressing human urinary bladder cancer J82 cells vol.137, pp.3, 2011,